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ABSTRACT 
Prevention of infection remains a challenge to the implementation of the 
percutaneous osseointegrated implant technology of prosthetic limb attachment in 
amputees. The purpose of this investigation was to determine if a broad spectrum 
antimicrobial, Ceragenins™ (CSA - 13), could prevent pin track infections in a 
percutaneous pin wound site in a sheep model. 
The pin was inserted through both cortices of the proximal tibia and protruded 
through the skin on the medial side of the hind leg. All twenty sheep received the 
smooth titanium alloy pin. Ten sheep were treated with a polyurethane foam pad 
coated with a CSA-13-polyurethane polymer conjugate, and ten sheep served as 
controls receiving an uncoated, sterile foam pad. The sheep were euthanized at the 
end of the 24-week trial or when they presented with clinical signs of pin track 
infection. After euthanasia, cultures were obtained of muscle, blood, and bone, and 
muscle and bone were harvested for histology. In addition to the clinical signs of 
infection, the sheep was considered infected if at least one tissue culture was positive 
and/or one histologically stained sample was found positive. 
Statistical analysis included Kaplan-Meier survivorship curves to display time 
to pin track infection rates and the Wilcoxon-Mann-Whitney test to compare the 
Appositional Bone Index between the groups. 
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The data demonstrated that, when compared to the control pads, the CSA-13-
polyurethane conjugate coated pads did not prevent pin track infection (p=0.88). All 
sheep were euthanized during the first 40 days after implantation. Large gaps around 
the pin indicated a lack of skin-pin adhesion. Radiographic implant loosening was 
found in both CSA-13 and untreated control groups. Fibrous tissue formation was 
found in the gaps between the implant and bone. Skin and soft-tissue motion may 
have led to micromotion along the implant, which in turn led to pin track infection 
and/or implant loosening. 
CSA-13 was not effective in preventing pin track infections in a percutaneous 
sheep model in the application used. The data suggest that maintaining skin 
attachment to the implant surface is essential and that antimicrobials may only be 
used as secondary barriers following skin attachment. 
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BACKGROUND AND INTRODUCTION 
Source of Amputations 
Sixty-four percent of those injured in World War I survived their injuries 
while 72% of those injured in the Vietnam War survived. About 87% of those 
injured in Operation Iraqi Freedom and 68%) of those injured in Operation Enduring 
Freedom are surviving.1 , 2 Of this current greater percentage of surviving wounded 
warriors, 2% from Operation Iraqi Freedom have one or multiple amputations 
compared with 3% in Vietnam and 1% in WWL 1 
A closer examination of one airman demonstrates the type of injuries a 
warrior can sustain and survive currently. This patient lost one lower extremity above 
the knee, the other in a hip disarticulation, as well as his right hand, and a portion of 
his face. This airman survived these injuries because of the vastly more advanced 
medical care found closer to combat zones than the care available in previous wars. 
A functional hospital can now be located within 60 minutes of a battlefield.-
Surgeons and medical professionals are now taught to immediately resuscitate, 
stabilize and debride all wounds to keep the wounded warrior alive and maintain a 
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sophisticated levels of surgical care and final wound closure. These treatment tactics 
are saving lives that would have been lost in previous wars. 
Another life-saving system that has been implemented on the current 
battlefield is the proper training and use of tourniquets. Once thought of as a "danger 
to life and limb"J in 1918, views and studies on tourniquets have shown them to have 
great potential as life-saving devices without jeopardizing limb survival. All military 
personnel are now trained in the use of and carry tourniquets. Tourniquets have 
become standard issue to each warrior on the battlefields of Iraq and Afghanistan.4 
Current Treatment of Amputees 
With survival there are now new challenges in the aftercare and treatment of 
these wounded warriors, especially those with high level, multiple amputations. 
Conventional socket prosthesis attachment is extremely difficult on a short residual 
limb. Limited residual limb length requires complex docking mechanisms. Also, 
sockets are difficult to attach to a short residual limb and may impinge on the 
proximal joint (pelvis or shoulder girdle) when the artificial limb is moved.5 Other 
problems associated with socket technology include heat and sweating in the 
prosthetic socket, sores/chafing, and skin breakdown as well as the more complex 
skin problems of infection and skin lesions. Sockets limit the ability to walk quickly 
or adequately power a prosthetic hand.6 ' 7 There are also problems maintaining a good 
fit due to weight fluctuations and pain. Trans-femoral socket technology can cause 
discomfort when sitting and reduce the range of motion of the hip. 
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Osseointegration 
To increase range of motion, give an increased level of comfort when sitting, 
and even allow the possibility of osseoperception (sensory input through the 
prosthesis),8'9 osseointegrating implants directly with the bone of the residual limbs 
has been introduced and found to increase the quality of l ife 6 of amputees, especially 
patients with short residual limbs. 
Dr. Rickard Branemark has developed a two-stage implant procedure for 
osseointegration.1 0 This procedure involves screwing the implant into the bone, 
closing the wound site, and allowing healing for 6 months. A percutaneous abutment 
is then screwed into the implant during the second operation. A year of progressive 
loading under the supervision of a physical therapist then follows.1 0 ' 1 1 
Infection was initially the most common complication encountered by 
Branemark, in a 3-year follow-up of the first 16 transfemoral patients to receive the 
percutaneous implant. Fourteen superficial infections and seven deep infections were 
reported. Other complications included abutment, abutment screw, and fixture 
(implant) failure.1 1 
The infection control strategy in the Branemark model includes his surgical 
technique where the skin is adhered operatively to the distal region of the bone. Strict 
daily hygiene is mandated that involves the use of a cotton flossing cloth, moistened 
1 o 
with sterile saline, which is spun around the skin-implant interface. " This flossing 
may reduce the bacteria burden, debride cellular residue, and possibly remove and 
prevent biofilm formation. 
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with sterile saline, which is spun around the skin-implant interface. 12 This flossing 
may reduce the bacteria burden, debride cellular residue, and possibly remove and 
prevent biofilm formation. 
4 
The Branemark osseointegration two stage procedure to treat transfemoral 
amputees has also been performed in the United Kingdom. After 1 year, 2 of the 11 
13 
patients (11%) had their abutment and internal fixture removed because of infection. 
Limitations to current applications of osseointegration technology include the 
risk of infection, implant loosening, and implant breakage. Two types of infection 
can develop: infection at the implant-skin interface (superficial) or deep infection. 
Deep infection can lead to life-altering consequences including chronic infection, 
bone resorption leading to bone fracture or implant loosening, and possible eventual 
reamputation at a higher leve l . 1 1 , 1 3 , 1 4 The development of an effective infection-
prevention strategy is crucial to combat these destructive, debilitating, and 
unacceptable infections. 
Staphylococcus aureus has been found as a source responsible for biomaterial, 
device-related, and/or pin track infections1 5 ' 1 6 Staphylococcus aureus can tolerate 
high saline levels as shown by the Mannitol Salt Agar S. aureus detection method 
where S. aureus grows on plates containing 7'.5% saline. ' S. aureus as a prominent 
infectious agent in pin track infections thriving in high concentrations of saline leaves 
suspect the Branemark method of infection prevention through flossing with a cloth 
moistened with saline. Thus, an alternative barrier to saline should be explored. 
Options for Treatment of Infection in Osseointegrated Prosthetics 
Antimicrobials are molecules that can kill or slow the growth of an infection-
causing microbe. Resistance has developed to many traditional antibiotics. 1 9 ' 2 ( ) An 
example is Staphylococcus aureus, which has in a step-wise fashion developed 
resistance to penicillin (via beta-lactamase production), resistance to methicillin 
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21 (MRSA via penicillin-binding protein, PBP2a production coded by the mecA gene)," 
and now is in the early stages of developing resistance to vancomycin. ~ Changes in 
the bacterial cell wall chemistry are important in the resistance-development 
process.2 1 Two events can cause antibiotic resistance. The first is horizontal gene 
transfer between individuals in a bacterial population. The second is mutations 
encoded in the chromosome of the bacteria.2 0 These horizontally transferred genes 
are transferred by episomes, which are genetic particles within certain cells that can 
2 3 
exist either autonomously in the cytoplasm or as part of a chromosome. 
To combat these resistance-developing bacteria, novel antimicrobials are 
currently being developed and studied. Antibacterial peptides have been isolated 
from diverse organisms2 4 ' 2 5 and these peptides are, in general, cationic and facially 
amphiphilic molecules. They display broad-spectmm antibacterial activity, rapid 
killing times, and are less likely to induce the formation of resistant stains of bacteria. 
The mechanism for their lethal action against bacteria is permeabilization or 
disruption of the bacterial cell membrane. At high concentration these cationic 
peptides can be toxic to mammalian cells which are enveloped by a cell membrane 
which is similar to the cell membrane found in bacteria. Pexiganan is an example of 
an antibacterial peptide that has been studied in vitro and in a transcutaneous bone/pin 
rabbit model and found to have bactericidal properties. Although pexiganan, 
isolated from the African clawed frog, demonstrated bactericidal properties, the 
company producing the product abandoned the pursuit of FDA approval because of 
difficulties in maintaining manufacturing consistency. 
(  i  i illi - i i  r t i ,  r ti    t  cA e),21 
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exist either autonomously in the cytoplasm or as part of a chromosome?3 
To combat these resistance-developing bacteria, novel antimicrobials are 
currently being developed and studied. Antibacterial peptides have been isolated 
from diverse organisms24,25 and these peptides are, in general, cationic and facially 
amphiphilic molecules. They display broad-spectrum antibacterial activity, rapid 
killing times, and are less likely to induce the formation of resistant stains of bacteria. 
The mechanism for their lethal action against bacteria is permeabilization or 
disruption of the bacterial cell membrane?5 At high concentration these cationic 
peptides can be toxic to mammalian cells which are enveloped by a cell membrane 
which is similar to the cell membrane found in bacteria. Pexiganan is an example of 
an antibacterial peptide that has been studied in vitro and in a transcutaneous bone/pin 
rabbit model and found to have bactericidal properties?6 Although pexiganan, 
isolated from the African clawed frog, demonstrated bactericidal properties, the 
company producing the product abandoned the pursuit of FDA approval because of 
difficulties in maintaining manufacturing consistency. 
6 
Pexiganan illustrates a limitation to the use of naturally derived antibacterial 
peptides. Because of their relatively large size (> 20 amino acids), manufacturing 
antibacterial peptides can be technically difficult and costly. For example, at the 
current production efficiency with the available manufacturing techniques, for each 
100 kg of recombinant peptide, one million liters of fermentation mixture is 
necessary. This creates a cost that is 5 to 20 times as high as that of conventional 
antibiotics.2 7 Many of these peptides also have short lifetimes in the presence of 
proteases.2 8 Because of these limitations, antimicrobial focus has shifted to 
developing mimics of these naturally effective cationic antimicrobials. 
One such mimic was developed by the synthesis of steroids with amine 
groups. This novel series of antimicrobial compounds, termed Ceragenins, is based 
on derivatives of bile acids with covalently attached amines (Figure 1.1). CSA-13 
is the most potent of the Ceragenin compounds tested to date" and has been shown in 
o n 
vitro to effectively kill both gram-negative and gram-positive bacteria. Although 
29 
Ceragenins have been found to have weak hemolytic activity," they display broad-
spectrum bactericidal activity,3 1 which made them an optimal antimicrobial choice for 
this study. 
Model to Test Infection Prevention 
A model was needed that would provide a challenging environment for testing 
the chosen antimicrobial, an environment that would preferably mimic the possibly 
contaminated situations encountered by an active warrior amputee. The model also 
needed to mimic the large amount of soft tissue motion observed clinically in the 
distal ends of residual limbs of the local veteran amputee population. The test model 
    
 
  lt  
  i  
    
 
i tics.27     
ses.n   
  .
    
  
  ib'U .29 
    29   
vitro to effectively kill both gra -negative and gra -positive bacteria. 3o lthough 
Ceragenins have been found to have weak hemolytic activity,29 they display broad-
spectrum bactericidal activity,3! which made them an optimal antimicrobial choice for 
this study. 
Model to Test Infection Prevention 
A model was needed that would provide a challenging environment for testing 
the chosen antimicrobial, an environment that would preferably mimic the possibly 
contaminated situations encountered by an active warrior amputee. The model also 
needed to mimic the large amount of soft tissue motion observed clinically in the 
distal ends of residual limbs of the local veteran amputee population. The test model 
7 
CSA-13 
Figure 1.1: CSA-13 structure displaying steroid backbone and attached amine groups 
giving the structure its characteristic amphipathic (both hydrophilic and hydrophobic 
groups) morphology 
should not mimic the Branemark operative procedure, which removes the soft tissue 
aspect of the residual limb to create a skin seal around the bone. 1 0 This is because the 
use of that operative procedure would cause difficulty in distinguishing between the 
advantages of skin immobilization which alone has been shown to reduce 
percutaneous infection from a mobile skin site and the chosen primary infection 
barrier CSA-13. The test model was also not meant to mimic the goat model chosen 
by Pendegrass to facilitate dermal attachment into flanged implants placed in the 
relatively stable distal end of the medial aspect of the tibia. Those implants were not 
subject to large mechanical forces from soft tissue impacting the implant. 3 4 
A sheep model was chosen because of previously successful studies on bone 
and fracture healing using this animal. ' The chosen model was also a modification 
of a previously used rabbit model which had a highly mobile skin site at the Bone and 
Joint Research Lab (SLC, UT) that proved ineffective at keeping the antimicrobial at 
the wound site due to animal behavior.2 6 That rabbit model failed because the rabbit 
was able to access the tibial pin site notwithstanding the use of Elizabethan collars, 
plastic caps, and conforming bandages. This implant site access was in contrast to an 
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effective wound healing rabbit model that implanted the percutaneous device into the 
back of the animal.3 7 That model, although effective at preventing animal disturbance 
of the implant site, did not allow the desired highly mobile skin site. 
The chosen model for this study also needed to show successful infection in 
the control animals to demonstrate the type of infections currently seen in the 
osseointegrated amputees1 1 as well as provide a challenge for the CSA-13 to act as 
the primary barrier to infection. In a previously tested rabbit percutaneous model 
with the implant inserted into the tibia near the ankle joint, only 1 in 10 of the test 
rabbits experienced an exit-site infection. This low infection rate was improved in 
the Bone and Joint Research Lab rabbit model, but animal behavior was a detriment 
which led to the use of the sheep model. The proximal end of the tibia was kept as 
the surgical implantation site in the chosen sheep model to allow for maximal soft 
tissue motion around the implant site. 
Hypothesis Tested and Rationale 
The sheep animal model and medial, proximal tibial site of surgical 
implantation were chosen based on animal behavior, soft tissue motion, and the 
ability to test an antimicrobial as a primary barrier to infection. This animal model 
allowed testing of the following hypothesis: 
A cationic steroidal antimicrobial (CSA-13) as a medical device 
will prevent pin track infections at a mobile, soft tissue, percutaneous implant 
site in a sheep model. 
CSA-13 was chosen to act as a primary barrier to pin track infection at a percutaneous 
implant site with surrounding highly mobile soft tissue. 
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CHAPTER 2 
MATERIALS AND METHODS 
Implant Design 
All implants were titanium alloy (Ti-6A1-4V) and manufactured by the 
University of Utah School of Medicine Machine Shop. 
A pilot study was conducted in two sheep with an implant 120 mm long with 
28 mm of threading that transversed both the medial and lateral aspects of the tibia. 
This model was found to be too aggressive because the skin on the lateral side was 
excessively mobile causing difficulty in keeping the pads at the wound site. Another 
problem with the model was that there was wool on the lateral aspect and hair on the 
medial aspect of the tibia making the comparison unequal. Because of these findings 
from this pilot study, the implants were shortened and the surgical procedure slightly 
altered to make the implants protrude from the skin on the medial side only (Figures 
2.1 and 2.2). Modified implants were made 95 mm in length with a 5 mm diameter. 
A 10 mm long, 1 mm deep notch was cut into the metal 5 mm away from the exposed 
portion of the implant (Figures 2.1 and 2.2). At the opposite end a 28 mm length of 
threading was located 5 mm from the tip. Implants were passivated using citric and 
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Figure 2.1: Photo of the 5 mm diameter, 95 mm long, titanium alloy implant. The 
arrow indicates the notch preventing the Jurgen ball from being displaced. The 
Jurgen ball assured the pad was in contact with the skin-implant interface. 
Figure 2.2: Anterior-posterior contact radiograph of pin placement in sheep tibia. 
Notice the medial tibial entry point at the medial-coronal portion and approximately 
one cm distal to the knee joint line. 
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Experimental Groups and Infection Prevention 
All animal protocols and amendments were reviewed and approved by the 
Salt Lake City, Utah, Veterans Affairs Institutional Animal Care and Use Committee 
(IACUC) and the University of Utah IACUC in accordance with NIH guidelines. 
Twenty nonpregnant adult Rambouillet ewe sheep, ranging from 2.5 - 6 years 
old with weights of 75-90 kg, were used in this study. The sheep were randomized 
into two groups, one consisting of 10 untreated baseline controls and the other the 10 
test sheep. Approximately 25 mm outer diameter, 4 mm inner diameter, 2-5 mm 
width polyurethane foam pads (Rynel, Inc., Wiscasset, ME, USA) were prepared as a 
vehicle for the cationic steroidal antimicrobial (CSA-13)-polyurethane polymer 
conjugate (Cerashield™, Ceragenix Pharmaceuticals, Inc., Denver, CO). The 
polyurethane used to conjugate with the CSA-13 had a high acid number (19) (AST 
Products, Inc., Billerica, MA) in contrast with the polyurethane foam pads used in 
both groups which were not acidic. These pads had a central circular hole that 
allowed the pad to fit tightly over the implant and cover the skin-implant interface. 
Ten sheep were treated with the CSA-13-polymer conjugate that was coated onto the 
polyurethane foam pads. Ten control baseline sheep received autoclaved 
polyurethane foam pads without the CSA-13-polymer conjugate. CSA-polyur ethane 
polymer coated pads and the control pads remained at the implant site for the length 
of the study and were changed at least weekly or more frequently in the first days of 
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Surgical Preparation 
The animals were fasted for approximately 12 hours prior to surgery and 
given an oral bolus of Tetracycline (0.5 gram-1.5 gram 12 hours preoperatively and 
0.5 gram - 1 gram 1 hour before surgery) to reduce rumen bacterial activity. An IV 
catheter was placed in the jugular vein and secured. The anesthesia induction dose 
was calculated using the animals' receipt weight. 
Baseline nose, throat and skin swabs were obtained for culture using standard 
microbiological procedures. This was to determine the normal flora of the sheep at 
time zero. Animals were initially anesthetized with an intravenous injection of 
diazepam (0.1-0.5 mg/kg) and an IM injection of ketamine hydrochloride (4.4-7.5 
mg/kg to effect). They were intubated and maintained under anesthesia with 
isoflurane (0.5-5% to effect) in oxygen delivered with a rebreathing anesthesia 
circuit. A rumen tube was placed as needed to control regurgitation. Lactated 
Ringer's solution was administered via the IV catheter throughout the procedure at a 
rate of approximately 15 ml/kg/hr. 
The hind leg and area over the sacrum and the dorsal aspect of the neck was 
close-shaved. A 50 ug Fentanyl patch was placed on the neck and a bandage placed 
over it to protect the patch. The animal was positioned in ventral recumbence and the 
area over the sacrum was prepped with betadine scrub, alcohol and betadine solution. 
Morphine (0.1 mg/kg not to exceed 10 mg total dose) was given as an epidural to 
provide post operative analgesia. The animal was then positioned on a warm water 
recirculating blanket in lateral recumbence with the operative limb to up. Anesthesia 
monitoring included: respiratory rate, tidal volume, end tidal CO2, heart rate, and 
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oxygen saturation. The animal was prepped for surgery by scrubbing from the 
surgical site outward with a betadine scrub followed by a 70% alcohol wipe. This was 
repeated three times with a brief dry time and final spray of betadine solution. 
Surgical Technique 
Once the animal reached a surgical level of anesthesia, the surgical procedure 
began. Because the skin at the level of the sheep's knee is highly mobile, the site of 
the medial skin wound was determined to allow the skin tension on the implant, once 
inserted, not to be excessive when the limb was in full flexion or extension and 
minimal when the limb was in a normal standing at rest position. An appropriate 
medial tibial entry point at the medial-coronal portion and approximately one cm 
distal to the knee joint line was determined (Figure 2.2). A 2.5 mm guide wire was 
then driven across the tibia and pierced the lateral cortex in the coronal plane. Care 
was taken to avoid the digital extensor foramen. Accurate implant placement was 
verified with a mobile C-Arm image intensifier (Series 9800™ Mobile C-Arm, lk x 
lk Mobile Workstation, OEC Medical Systems, Inc., Salt Lake City, UT). 
A #15 blade scalpel was then used to enlarge the medial incision to accept a 5-
mm cannulated reamer which reamed across both cortices. During reaming the skin 
surrounding the incision was secured using a drill sleeve (Figure 2.3). 
The implant was then drilled across both cortices with the lateral blunt end of 
the implant extending only 3 or 4 mm beyond the bone and buried in the lateral soft 
tissues. The medial end of the implant protruded approximately 1 .5 -3 cm outside the 
skin and allowed for attachment of the control and antimicrobial pads. 
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Figure 2.3: Drill sleeve (S) and cannulated drill bit (B) used during surgery. 
Depending on the group to which the sheep was randomly assigned, CSA-
polyurethane polymer coated or uncoated control, sterile blank polyurethane foam 
pads were placed at the medial implant-skin interface. Two CSA-13-polyurethane 
conjugate or two control pads stacked on top of each other were placed with one pad 
being in direct contact with the skin-implant interface (Figure 2.4). The initial 
removal torque was measured using a torque indicator (Dillon Quantrol™ AFTI 
Advanced Force/Torque Indicator, Meldrom Scale Co., UT). The torque indicator 
was set to measure data in a counterclockwise fashion. A silicon/Teflon washer was 
placed on top of the pads. To prevent irritation of the sheep apposing flank by the 
implant rubbing against it, a modified Jurgen ball was placed and tightened into the 
notch machined into the pin with its top flush with the tip of the implant (Figure 2.4). 
Anesthesia was discontinued and the animal was recovered from anesthesia. 
The animal was placed in its cage after it was determined that it was breathing on its 
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Figure 2.4: Completion of surgical procedure. Placement of pads (arrow), washer, 
and modified Jurgen ball (B) for maintaining pad contact at the skin-implant 
interface. 
own. Recovery was monitored until the animal was able to stand unassisted. Feed 
was returned at this time. 
Flunixin (1.1-2.2 mg/kg) and Ceftifur (Excenel) (1.1 - 2.2 mg/kg) were 
administered daily IM for 48-96 hours postoperatively. 
Pad Exchange Protocol 
During pad exchange, the modified Jurgen ball and silicon/Teflon washer 
were removed and wiped with isopropyl alcohol. To reduce the risk of contamination, 
when a new pad was placed at the skin-implant interface, the implant was wiped with 
Betadine followed by alcohol. Care was taken not to allow the Betadine or alcohol to 
contact the wound site, preventing an additional variable of antimicrobial treatment. 
Pads were aseptically removed and a swab was taken of the wound site for bacterial 
growth determination. The pads were placed and the swabs streaked onto Columbia 
blood agar (Hardy Diagnostics, Santa Maria, CA) and left overnight at 37° C for 
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observation the following day. The wound site was gently irrigated with 20-30 ml of 
sterile saline and dabbed with sterile gauze which removed varying quantities of dried 
exudates. Two new pads (CSA-13-polymer conjugate coated or sterile, depending on 
the group) were placed over the implant and lightly pressed against the wound site 
followed by a clean silicon/Teflon ring and Jurgen ball. 
Euthanasia Criteria 
The study team observed the sheep daily for general health and signs of 
infection. Euthanasia was performed when the implant site had Grade II clinical 
signs of infection as described by Checketts et al.: 1. Redness of skin, 2. Discharge 
from the implant site, and 3. Pain and tenderness in soft tissues or showed Grade I 3 9 
clinical signs of infection as demonstrated by slight redness around the implant with 
slight discharge with one or more of the following: 1. Appetite suppression, 2. 
Limited water consumption, 3. Lethargy, 4. Distress/limping, and/or 5. Pain and 
tenderness at the implant site. 
If the animal had one or more of the previous and/or unforeseen complications 
with the model design such as implant loosening, the animal was also euthanized. 
Microbiologic Cultures 
Immediately prior to euthanasia the sheep was calmed by an intravenous 
injection of 5 ml of Ketamine. Betadine and alcohol were applied liberally at the 
jugular vein site. Approximately 5 cc of blood were drawn aseptically and transferred 
to an aerobic blood culture bottle (BD BACTEC™ Plus Aerobic/F Medium, 50/sp, 
catalog # 442192, Franklin Lakes, NJ). Euthanasia was then performed by an IV 
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injection of Beuthanasia D at approximately 1 mL per 10 lbs of body weight. The 
pads, either control or CSA-13, were removed from the implant site and a swab for 
culture was taken. A swab distal to the implant site was likewise taken to determine 
if normal flora bacteria were contributors to the infection. The implant site and 
surrounding areas were then clipped and sterilized using Betadine/alcohol. 
A 7 mm biopsy punch was used to take a tissue sample 5 mm away from the 
implant insertion site (to keep the tissue-implant interface intact for light microscope 
analysis and histology) and through sterile skin. This allowed evaluation of the 
tissues deep into the implant insertion site for infection. Tissue was placed in 
Fastidious Broth (Hardy Diagnostics, catalog #K31, item #15923, Santa Maria, CA). 
The pin was wiped clean with alcohol and an extraction torque measurement was 
obtained using the torque indicator. A bone marrow sample was obtained for culture 
after aseptically removing the lower half of the tibia and swabbing through the 
medullary canal nearest to the implant insertion site. The limb was disarticulated at 
the knee joint and placed in formalin for further histological processing. Pads and 
swabs were cultured on Columbia blood agar overnight at 37° C whereas the blood 
culture bottle was incubated for 48 hours and subsequently plated on Columbia blood 
agar overnight at 37° C. The tissue sample in broth was incubated overnight at 37° C 
then streaked onto Columbia blood agar and incubated overnight at 37° C. The 
presence or absence of bacteria was observed qualitatively indicating a positive or 
negative infection. Isolates were permsaved for future identification. 
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presence or absence f bacteria as observed qualitatively indicating a positive or 
negative infection. Isolates ere per saved for future identification. 
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Imaging 
Gross photos were taken of all implant-containing specimens. Radiographs 
were then taken at 70 kV for 90 seconds on AGFA Scopix CR5B Electronic Imaging 
Film (AGFA HealthCare, Branchburg, NJ), using the Faxitron Cabinet X-Ray System 
Model 43855A (Faxitron X-RAY LLC, Wheeling, IL), and AGFA CP 1000 X-ray 
Film Processor (AGFA HealthCare, Branchburg, NJ) (Figure 2.2). 
Histology 
Tissue samples were obtained using a scalpel from an area directly superior 
and inferior to the implant site. These samples were dehydrated using a Vacuum 
Infiltration Processor (Tissue Tek Vacuum Infiltration Process, Miles Scientific, 
Elkhart, IN) and embedded in paraffin (Surgipath Medical Industries, Inc., Richmond, 
IL) using the Histocentre 2 embedding center (Thermo Shandon, UK). They were 
then sliced to 5 urn using a Reichert-Jung (Leica) 2050 Microtome (Leica 
Microsystems Inc., Bannockburn, IL) with Accu-Edge" Low Profile Blades (Sakura 
Finetek U.S.A., Inc., Torrance, CA). At least three slices were obtained from each 
sample. The slices were then placed on slides and cover slipped for staining. 
Bone samples were obtained by using an 8 mm outside diameter (6 mm inside 
diameter) screw extracting bit in conjunction with a United Heavy Duty Drill Press 
Model No. 810 (United by New Corp, Las Vegas, NV). Two samples were taken on 
the superior side on the medial and lateral aspects and one sample was taken on the 
inferior side. 
The bone samples were decalcified, dehydrated, and embedded in paraffin. 
They were then cut to 5 um widths using a microtome and cover slipped for staining. 
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Stains performed on both bone and tissue samples were the Brown-Brenn modified 
gram stain, Peroidic Acid-Schiff (PAS), and Hematoxylin and Eosin.2 6 The Brown-
Brenn stain was used to detect the presence of bacteria. The periodic acid-Schiff 
stain was used to detect the presence of fungus and the H&E stain was used for 
observing inflammation and fibrosis. The H&E stain was performed using a Microm 
DS 50 Slide Stainer (Richard-All an Scientific, Kalamazoo, MI). The Brown-Brenn 
stain and PAS stain were performed at ARUP Laboratories (Salt Lake City, UT). All 
histological analyses were performed by a board-certified pathologist at ARUP, while 
blinded to the study groups. 
Methyl Methacrylate Embedment and Contact Radiography 
Specimens containing implants were cut superior and inferior to the implant 
approximately 2-5 cm near the implant using a water saw (Manned Inc., Cleveland, 
OH). These cut specimens were then dehydrated using a Vacuum Infiltration 
Processor (Tissue Tek Vacuum Infiltration Process, Miles Scientific, Elkhart, IN) set 
on a 72-hour cycle that consecutively soaked the specimens in 70% Ethanol, 80% 
Ethanol, 95% Ethanol, 100% Ethanol, and the clearing reagent Xylene (Richard-
Allan Scientific, Kalamazoo, MI). These specimens were then placed in a container 
of a freshly prepared solution (Solution A) containing 800 mL methyl methacrylate 
(MMA) (Sigma-Aldrich Co., St. Louis, MO) and 200 mL n-Butyl Thalate (Sigma-
Aldrich Co., St. Louis, MO) with constant stirring at room temperature. Specimens 
were left in Solution A for at least 5 and no more than 10 days. Specimens were then 
transferred to a freshly prepared Solution B (800 mL MMA, 200 mL n-Butyl Thalate, 
2.5 gm Perkadox 16 (Akzo Nobel, Dayton, OH). These specimens in a container 
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containing Solution B were then placed in a vacuum desiccator refrigerated at 
approximately 4°C and left for at least 7 and not more than 10 days. The specimens 
were then removed from refrigerations and allowed to equilibrate to room 
temperature. They were then immersed in a container containing Solution C (800 mL 
MMA, 200 mL N-Butyl Thalate, 5 gm Perkadox 16). The specimens were then 
placed back into the vacuum desiccator at 4°C for at least nine but not more than 10 
days. The specimens were then removed from the vacuum desiccator and 
refrigeration and allowed to equilibrate to room temperature. Solution C was 
prepared and specimens were placed in a polypropylene container with a pre-
polymerized layer. Fresh Solution C was poured into the container to create a 1-3 cm 
layer which was allowed to polymerize under UV light at room temperature under a 
fume for 1-2 days. One to three cm layers were then consistently added until the 
specimen was completely embedded with a 1-3 cm layer covering the top of the 
40 
specimen. 
Individual specimens were then cut with an industrial vertical band saw 
(Model 20, Rockwell International, Pittsburg, PA) to remove excess MMA and 
reduce the size of the specimen for grinding. 
Specimens were then ground on an 8-inch Buelher Polimet 1 Polisher 
(Buehler Ltd, Lake Bluff, IL) using a 60 grit grinding paper (Silicon Carbide Wet/Dry 
C Weight, Leco Corp., St. Joseph, MI) and grinding until the implant width was fully 
visible. A slow, continuous drip of tap water onto the grinding wheel was maintained 
during grinding. 
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(Model 20, Rockwell Intemational, Pittsburg, P A) to remove excess MMA and 
reduce the size of the specimen for grinding. 
Specimens were then ground on an 8-inch Buelher Polimet 1 Polisher 
(Buehler Ltd, Lake Bluff, IL) using a 60 grit grinding paper (Silicon Carbide Wet/Dry 
C Weight, Leco Corp., St. Joseph, MI) and grinding until the implant width was fully 
visible. A slow, continuous drip of tap water onto the grinding wheel was maintained 
during grinding. 
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These sections (now between 3-5 mm thick) were then radiographed at 70 kV 
for 35 seconds on AGFA Scopix CR5B Electronic Imaging Film (AGFA HealthCare, 
Branchburg, NJ), using the Faxitron Cabinet X-Ray System Model 43 855A (Faxitron 
X-RAY LLC, Wheeling, IL), and AGFA CP 1000 X-ray Film Processor (AGFA 
HealthCare, Branchburg, NJ). 
Scanning Electron Microscope Imaging and Analysis 
Three untreated control specimens and four CSA-13 treated specimens were 
ground on the 8 inch grinding wheel with a slow continuous drip of tap water. Sixty, 
240, 400, and 600 grit papers were used sequentially to achieve a fine finish. The 
specimens were then polished using a polished cloth attached to the polishing wheel 
sprayed with 1 um alpha alumina. The slow, continuous drip of tap water was also 
maintained during polishing. The specimen was polished until the fine grain from the 
final grit paper was completely removed. The specimen was then rinsed under tap 
water and dried using a clean cloth (Kimwipe, Kimberly-Clark, Tucson, AZ) resulting 
in a mirrored finish. 
These polished specimens were then sputter coated with carbon for 15 
seconds using a carbon coater (Model Number 208, Cressington Scientific 
Instruments Ltd., Watford, England). The carbon coated specimens were individually 
placed in a JSM-6100 Scanning Electron Microscope (SEM) (JOEL USA, Inc., 
Peabody, MA) equipped with a backscattered electron detector (Tetra, Oxford 
Instruments Ltd, Buckinghamshire, UK) and attached image capture software (Noran 
System Six, Thermo Scientific, Madison, WI). SEM settings were set at the 
following: voltage: 20kV, working distance: 15 mm, probe current: -0.9 nA. The 
   Y
ab>1n
    (
     
  
   
 
    
11  alpha alu ina. The slo , continuous drip of tap ater as also 
    
     
  
i i . 
     
   i
,  
     
  
 r  
   
Y   
22 
probe current was measured with a SM-16100 probe current detector (JOEL USA, 
Inc., Peabody, MA) attached to an external picoammeter (Keithley Instruments, 
Cleveland, OH). Fine alterations in probe current were made frequently throughout 
image acquisition. To obtain images of a larger portion of the pin-implant interface, 
probe current was changed to approximately -3.0 nA and working distance was 
altered to 34 mm at 12x magnification or 39 mm at lOx magnification. 
Microscope Analysis 
Six 3-5 mm sections (two untreated control and four CSA-13 treated) were 
glued to plastic slides and ground to 50-70 um thick specimens. These specimens 
were then stained with Sanderson's Rapid Bone Stain using an Acid Fuchsin 
counterstain (Surgipath Medical Industries, Inc., Richmond, IL) and examined under 
light microscope (Nikon Eclipse E600, Nikon, Japan) with associated camera 
(Optronics, Goleta, CA) and image capture and processing software (Optronics 
MagnaFIRE™ SP version 1.0x5, Optronics, Goleta, California). 
Appositional Bone Index Measurements 
Appositional Bone Index (ABI) measurements4 1 were taken to quantify 
percent of bone in contact with implant upon euthanasia using Image Pro Plus 
software (Media Cybernetics, Inc., Bethesda, MD). Measurements of the areas of 
radiolucencies were also taken and divided by the length of possible bone-implant 
contact to provide an average width of radiolucency. These average widths of 
radiolucencies were compared between the untreated control and CSA-13 treated 
groups also using the Image Pro Plus software. 
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A log-rank test for equality of survivor functions was used to compare 
infection rates between the two study groups. A p-value of < 0.05 was considered 
statistically significant. Sheep were classified as infected if they demonstrated two or 
all three of the following: 1) Clinical signs greater than a Grade I infection as 
demonstrated by slight redness around the implant with slight discharge.3 9 2) Positive 
culture results for blood, soft tissue, and/or bone samples taken at euthanasia, and/or 
3) Positive bone and/or soft tissue histology results of samples processed after 
euthanasia. Kaplan-Meier survivorship curves were used to display these time to 
infection rates. The Fisher's exact test was used to compare clinical implant 
loosening and the Wilcoxon-Mann-Whitney test was used to compare the 
Appositional Bone Index (ABI) between the groups. A student t test was used to 
compare the average widths of radiolucencies between the groups as well as initial 
fixation torque. An analysis of covariance (ANCOVA) was used to compare final 
fixation torque. 
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The model was observed to be highly aggressive. The muscle and skin 
motion of the medial side of the tibia was observed to tear the skin surface and expose 
the underlying torn proximal ends of the fibularis tertius and extensor digitorum 
longus muscles. This led to gaps in the skin tissue ranging from approximately 15 
mm to 30 mm around the implant-skin interface, which indicated a lack of skin-
implant adhesion (Figure 3.1). 
Figure 3.1: Skin gap at pin (P) site created by movement of muscle and skin. Notice 
the skin boundary (arrow) and exudates (E) surrounding the pin/skin interface. The 
size of the gap is approximately 24 mm (solid white line). 
 
  
    
m  t /ibul  i s sor digitor
   
  ,    
  
:  t  
  . 
   
The wound site was observed to expand approximately 1 -7 mm beyond the 
diameter of the pads in 10% (1 of 10) of CSA-13 treated sheep and 30% (3 of 10) of 
untreated control sheep. Clinical signs of infection in addition to other signs of 
distress and model complications observed in the groups included high rates of 
redness, discharge, necrotic tissue, limping, the pad not covering the wound site, and 
swelling found in both the CSA-13 treated sheep and the untreated control sheep 
(Table 3.1). 
Infection Rates 
Eighty-five percent (17 out of 20) of the sheep had bacteria cultured in the 
blood, bone, and/or soft tissue samples taken at euthanasia. Of these 17, nine were 
CSA-13 treated and 8 were untreated controls. The CSA-13 treated group had one 
positive blood culture, nine positive soft tissue cultures, and zero positive bone 
cultures. The untreated controls had two positive blood cultures, eight positive soft 
tissue cultures, and three positive bone cultures. 
Eighty-five percent (17 out of 20) of the sheep had positive histology results 
showing small, gram positive rods indicative of infection. From these positive 
results, eight CSA-13 treated and nine untreated controls had positive histological 
results in soft-tissue specimens taken adjacent to the implant sites. One CSA-13 
treated and two untreated controls had positive bone histological results from bone 
samples removed either proximal or distal to the implant. 
Upon combining culture, histology, and clinical signs of infection results, it 
was determined that 95% (19 of 20) of the sheep were infected at euthanasia. Five 
percent of the sheep (1 of 20, CSA-13 treated) were euthanized due to clinical signs 
25 
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Figure 3.2: Kaplan-Meier curve showing that CSA-13 treated pads did not 
significantly prevent infection compared to untreated control pads (p=0.88). 
of infection but were not classified as infected because of negative culture and 
histology results. 
The infection data demonstrated that, when compared to the untreated control 
pads, the CSA-13 did not prevent pin track infection (p=0.88 with euthanasia as 
endpoint, p=0.16 with the endpoint being weekly observations conforming to the 
predefined definition of infection, Figure 3.2). 
All sheep were euthanized between 8 and 40 days after surgical implantation 
due to clinical signs of infection or animal distress. All sacrifices occurred prior to 
the intended 6-month endpoint. 
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Clinical Loosening 
Large skin gaps around the implant indicated a lack of skin-implant contact 
and extreme soft tissue mobility. Movement of muscle and contact with the apposing 
flank may have caused loading on the implant and micromotion leading to increased 
infection rates and implant loosening. The CSA-13 treated group had a higher rate of 
clinical implant loosening when compared with untreated controls (Fisher's exact test 
p=0.005). Nine of 10 sheep treated with CSA-13 had clinically loose pins at the time 
of sacrifice. In contrast, 2 of 10 untreated control sheep had clinically loose pins at 
time of sacrifice. 
Radiographic Loosening 
In addition to clinical implant loosening, radiographically determined implant 
loosening was examined. It was found that the CSA-13 treated group [median (IQR), 
1.4 (0, 11.2)] had a higher percentage of radiographic lucency and a lower ABI than 
the untreated control group [8.6 (0, 41.7)]. The variation in percent bone contact 
between the CSA-13 treated sheep and the untreated controls was not statistically 
significant (Wilcoxon-Mann-Whitney test, p = 0.53). This radiographic analysis 
suggested that both groups had clinically unacceptable radiographic lucencies, 
indicative of early implant loosening (Figure 3.3). 
Average width of radiographic lucencies was compared between the two 
groups and not found to be statistically significant (cranial side radiographic lucency 
widths, p=0.57; caudal side radiolucency widths, p=0.09). The average radiographic 
lucency widths from the control group were 1.00 mm (cranial side) and 1.11 mm 
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Out CO 9 14 15 18 21 31 32 32 40 
% 
Bone 
Contact 96 0 10 0 7 78 42 0 0 12 
CSA-13 Treated 
Figure 3.3: Contact radiographs of implant-bone interfaces for the 20 sheep. "Days 
out" signifies days from surgery to euthanasia. "% Bone Contact" is the length of the 
bone to implant interface along the threaded portion of the pin divided by the total 
length of the threaded portion of the pin after euthanasia (ABI). The radiographs 
clearly demonstrate that there was extensive radiographic loosening in both groups. 
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(caudal side). The average radiographic lucency widths for the CSA-13 treated group 
were 0.93 mm (cranial side) and 0.87 mm (caudal side). Fibrous tissue was visually 
observed within these gaps between bone and tissue. 
Histological Review 
Implant-bone interfaces as well as the area of bone immediately surrounding 
the interface site were histologically examined. Even after 25 days in situ, it was 
found that bone fragments did not incorporate with the host bone tissue in either the 
CSA-13 treated group or the untreated control groups at the bone-implant interface. 
The lack of healing response was in contrast to woven bone formation and 
remodeling, which were occurring approximately 1 -4 millimeters away from the 
implant site (Figure 3.4). 
Further histological examination of the pin-implant interface revealed viable 
osteocytes within microns of the interface which suggests that the bone was viable 
but that remodeling at the interface was arrested (Figure 3.5). These viable 
osteocytes are evidence that lack of bone remodeling at the interface was not due to 
necrosis of the bone caused by possible bone overheating during implantation. 
Fibroblasts and fibrous tissue were observed at the pin-implant interface 
which demonstrated a foreign body response to the implant (Figure 3.6). 
Lack of bone healing response at the implant-bone interface as well as woven 
bone formation millimeters away from this interface was also found using a scanning 
electron microscope (SEM) in backscatter electron imaging mode (Figure 3.7). 
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Figure 3.4: Demonstration of lack of healing response at bone-implant interface with 
healing response approximately 1 -4 millimeters away from interface, a) Untreated 
control, 32 days: Bone(B)-implant(I) interface showing unincorporated bone 
fragments without remodeling activity, b) CSA-13 treated, 25 days: Bone(B)-
implant(I) interface with bone fragments demonstrating no healing or remodeling 
activity, c) Untreated control, 32 days: Woven bone (WB) formation identified by 
osteoblast lining around the perimeter of the bone, d) CSA-13 treated, 25 days: 
Woven bone (WB) being created with osteoid secretion from osteoblasts lining the 
bone. Slides stained using Sanderson's Rapid Bone Stain, a, b, d original, uncropped 
images taken at magnification of 200x. c original image taken at magnification of 
1 OOx. c and d taken approximately 1-4 mm away from bone-implant interface. 
31 
 l    l t  
   -4 illi eters a ay fro  interface. a) Untreated 
l t    t  
ents   . , 
 fr     
.      i  
   .
     
'   .  , 
ti   .  i i ti   
00x. c and d taken approxi ately 1-4  away fro  bone-i pla t interface. 
32 
Figure 3.5: Viable osteocytes in bone located within microns of the implant in both 
untreated control and CSA-13 treated specimens, a) Untreated control, 8 days: Viable 
osteocytes (example circled) in bone within microns of the implant (I) demonstrating 
healthy bone at interface near the time of surgical implantation, b) CSA-13 treated, 
25 days: Viable osteocytes (example circled) also found within microns of the 
implant demonstrating that the bone remained healthy. These viable osteocytes 
demonstrate that the bone near the implant was not excessively heated causing bone 
necrosis during the surgical procedure. Slides stained using Sanderson's Rapid Bone 
Stain. Original images taken at magnification of 200x. 
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Figure 3.6: CSA-13 treated, 30 days: Demonstration of fibroblast formation (arrow) 
of fibrous tissue in foreign body response surrounding implant (I). Osteoblasts 
(examples within circle) and osteoclasts (examples within rectangle) activity also 
found within one millimeter of the implant but not directly at the interface. Slides 
stained using Sanderson's Rapid Bone Stain. Original image taken at magnification 
of lOOx. 
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Figure 3.7: Backscatter electron images of bone tissue showing lack of bone healing 
and/or lack of ongrowth on implant surface, a) CSA-13 treated, 30 days: showing 
lack of bone contact at bone-implant interface and woven bone formation 
approximately 2 - 4 mm away from the interface, b) Untreated control, 40 days: 
showing bone-implant interface with bone fragments with no healing or remodeling 
activity and woven bone formation approximately 2 . 5 - 4 mm away. 
Torque 
The time zero torque values measured for the CSA-13 treated group had a 
mean of 0.60 ± 0.47 N-m and a median of 0.43 N-m. The time zero torque values 
measured for the untreated control group had a mean of 1.29 ± 0.60 N-m and a 
median of 1.37 N-m. There was a statistically significant difference found in torque 
at time zero between the groups (p=0.02, student t test) showing that the untreated 
control group had a tighter initial fixation immediately following surgery. 
Controlling for this baseline difference, using an analysis of covariance, there was not 
a significant difference found in endpoint torque between the groups (p=0.80). 
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CSA-13 was not effective in preventing pin track infections along 
percutaneous implants in this study's sheep model. Because of other factors 
involved, such as excess amounts of skin and soft tissue motion at the foam pad-
implant site interface, this result does not conclusively exclude CSA-13 as a 
preventative barrier to pin track infections if a stable skin-implant interface could be 
established. 
Goals of Study 
The first goal of the study was to develop an animal model that would 
accurately represent the mobile soft tissue conditions at the distal end of the residual 
limb of active warrior amputees, unlike the Pendegrass et al. goat model. 3 4 The 
second goal was to examine the use of a broad-spectrum antimicrobial as a primary 
barrier to infection rather than skin immobilization followed by a saline flossing 
treatment as seen currently in the Branemark model. 1 0 A third goal was to develop an 
animal model that would have a strong infection signal, contrasting with the Gerritsen 
rabbit model which only had a 1 in 10 infection rate, in the control animals to 
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provide a signal that would possibly model an active amputee with retained residual 
limb distal soft tissue. 
The first goal was achieved as a highly mobile soft tissue interface at the 
implant site was observed around the percutaneous implant at the proximal end and 
medial region of the tibia. 
The second goal was not achieved, but the results support the idea that 
antimicrobials could only be used as secondary rather than primary barriers to 
infection in osseointegration. This leads to a need for further exploration of 
antimicrobial usage as a secondary barrier to infection. The goal of infection 
prevention using an antimicrobial as a primary barrier appeared to have been 
significantly hindered by the challenging animal model. The lack of success of 
preventing infection without skin immobilization supports the conclusion that soft-
tissue motion around the implant, although similar to that seen at the distal end of 
residual limbs in amputees, must be controlled and/or eliminated as a major operative 
and implant design component of the infection-prevention strategy before 
osseointegrated implant technology is introduced as a standard of care. 
The third goal was achieved as 10 of 10 untreated control sheep were infected 
prior to the 6-month predetermined endpoint of the study demonstrating that a 
strong infection signal was present in this model. 
Implant Loosening 
The time zero torque values measured were significantly different between the 
untreated control group and the CSA-13 treated group. The untreated control group 
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fixation could have been a key factor in the delay of clinical pin loosening observed 
in the untreated control group when compared with the observed clinical loosening in 
the CSA-13 treated group. 
Implant loosening was statistically more clinically apparent in the CSA-13 
treated sheep. This could have been caused, along with looser initial fixation in CSA-
13 treated group as stated previously, by CSA-13 causing a higher rate of hemolysis 
along the length of the implant. This increased amount of hemolysis and possible 
lysis of other cell types could have contributed to possible earlier tissue fibrous 
capsule formation along the length of the implant that limited bone healing and 
implant osseointegration. Further investigations are required to confirm this 
conjecture. This earlier clinical implant loosening initiated sheep blood agar 
hemolysis studies that demonstrated the a-hemolytic properties of CSA-13 when used 
at the concentration and in the delivery method chosen for this study. This a-
hemolytic response was in comparison with no hemolytic response caused by 
untreated control polyurethane polymer pads. 
Because this earlier loosening in the CSA-13 treated group was observed 
clinically but was not confirmed radiographically (as shown by radiographic 
lucencies in both groups and ABI) than the untreated control group, it is proposed that 
clinical loosening would have occurred with more time in the untreated control group. 
This concurrent radiographic loosening points to a factor other than CSA-13 as the 
cause of the observed detrimental effect of the extensive fibrous tissue formation 
limiting bone healing around the implant and osseointegration. 
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Another factor that could have contributed to both clinical and radiographic 
pin loosening was the initial implantation technique which allowed for a 0.5 mm 
circular gap in the bone on the medial aspect. This was because the threading in this 
investigational implant design was raised 0.5 mm (Figure 2.1). This raised threading 
design was unlike the threading chosen by Pendegrass et al. in a goat model which 
tested for implant fixation through dermal tissue ingrowth which did not report any 
clinical loosening.3 4 ' 4 2 Because this study's threading was limited to a combination of 
cancellous bone and cortical fixation on the lateral aspect of the bone (approximate 
unthreaded portion of pin in tibia: 15-30 mm, length of threading in each pin: 28 
mm), 15-30 mm of bone was not in apposition to the implant surface, but allowed for 
a 0.5 mm gap at the medial cortical bone region (Figure 2.2). This gap could have 
allowed fluid transport and mechanical loosening from micromotion of the implant 
when the soft tissue loads were applied during activity. Pressure was also applied to 
the implant site by the apposing flank when the sheep was resting in both a standing 
and lying down position. The resulting micromotion of the implant may have also 
contributed to initial bone resorption, fibrous tissue formation, and implant 
loosening. 3 
The gap along with skin and soft-tissue motion left a region around the 
implants where bacteria could track along the implant surface and cause infection. 
Excessive pin site tissue motion has been stated as one of the main clinical factors 
contributing to pin track infections.4 4 Infection observed in this investigation could 
have contributed to bone resorption and increased implant loosening. This agrees 
with findings from a study performed by Mahan et al., which found a direct positive 
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correlation between loose pins and positive cultures for infectious organisms.1 6 In 
conclusion, the muscle and skin motion observed clinically in the sheep model 
prevented a strong skin seal from being maintained in either group, could have caused 
micromotion, and possibly led to increased infection and increased implant loosening. 
Skin is an important physical barrier between an organism and its external 
environment. It also contains a specialized cutaneous immune system that consists of 
lymphocytes and antigen presenting cells that will generate and support localized 
immune and inflammatory reactions.4 5 Because of these properties, creating and 
maintaining a strong and viable skin seal around osseointegrated devices is crucial to 
infection prevention success. 
Fibrous tissue formation surrounding the implant that was visually observed 
for both treatment groups in the sections embedded in methyl methacrylate, as has 
been previously mentioned, was a possible factor in implant loosening. Hofmann et. 
al. found that when fibrous tissue was present at the interface between porous-coated 
devices and cancellous bone in humans, bone remodeling was prevented.4 6 Human 
cancellous bone ingrowth has been found to have a similar growth pattern as ovine 
cancellous bone formation.4 7 
Bone Viability Around Implant 
A factor examined histologically was determining the viability of the bone 
found at the implant-bone interface. Because viable osteocytes in the bone tissue 
were located within microns of some regions of the implant surface, initial concerns 
of possible overheating of the bone during the cannulated reaming part of the 
implantation surgical procedure was not considered a factor in preventing implant 
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incorporation with the host bone. The bone was found viable near the implant-bone 
interface where present (Figure 3.5). Because active bone remodeling was not found 
at these interfaces (Figure 3.4), other factors than bone viability were suspected such 
as early fibrous tissue formation. Factors in absence of bone remodeling at the bone-
implant interface could also include infection and/or tissue motion leading to 
micromotion along the implant surface.1 4 ' 4 8 
Study Limitations 
A previously mentioned study limitation was the raised threading design on 
the implant. 
Sheep Behavior 
The animals used were range animals not accustomed to human interaction 
and being housed indoors. This lack of previous human interaction was a probable 
cause of aggressive behavior in the animals when inspecting their implantation sites. 
Aggressive behavior led to animal handling challenges when performing weekly (or 
more frequent) pad exchanges which appeared to disturb the sheep. The sheep 
disturbance could have led to more aggressive sheep activity leading to more 
mechanical loads from the apposing flank of the sheep being placed on the Jurgen 
ball covering the implant. More mechanical disturbance meant more micromotion 
48 
along the length of the implant possibly contributing to implant loosening. 
This aggressive behavior was not observed in a similar goat study done by 
Pendegrass et al. 4 2 A possible explanation for the differences in animal behavior was 
the Pendegrass et al. model placing the implants more distally at a location containing 
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This aggressive behavior was not observed in a similar goat study done by 
Pendegrass et al. 42 A possible explanation for the differences in animal behavior was 
the Pendegrass et al. model placing the implants more distally at a location containing 
41 
a significantly smaller amount of soft tissue between the bone and skin. That 
placement encountered less mechanical forces being placed on the implants as well as 
no apposition between the animal flank and the implants. The current investigation's 
implant placement caused pain and distress that could have been caused by soft tissue 
shearing against the implant, another possible cause of animal aggressive behavior. 
CSA-13 Delivery Device 
Another study limitation could have been the delivery method chosen for the 
CSA-13. As mentioned, this device was a polyurethane foam pad coated with CSA-
13 conjugated to a hydrophobic, average MW 80,000, polyurethane with a high acid 
number (19). 4 9 This device was tested in vitro by immersing the CSA-13-polymer-
containing foam disk in 45 mL of phosphate buffered saline (PBS) for 24 hours. The 
disk was removed and the resulting solution was inoculated with either methicillin-
resistant Staphylococcus aureaus or tobramycin-resistant Pseudomonas aeruginosa to 
give ca. 106 CFU/mL. The bactericidal activity was determined at 2, 4, and 6 hours. 
The ceragenin-polymer releasing foam was placed into a fresh solution of PBS each 
day for 18 days. Even on the 18 t h day of resoaking the original ceragenin-polymer 
releasing foam, the solution inocula were eradicated by 6 hours. 3 0 
Alone, this in vitro testing did not completely depict the type of conditions 
experienced in the sheep model tested as the CSA-13 treated pad was not immersed in 
any solution before placement at the wound site. Thus the CSA-13 device was placed 
on blood agar, having been spread with a 0.5 McFarland standard of Staphylococcus 
aureus ATCC 49230, in a Kirby-Bauer-like fashion to perhaps more closely model 
the experimental situation. The CSA-13 device created a kill zone of ~5mm from the 
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outer edge of the pad. These results combined with the published in vitro results 
indicated that CSA-13 is effective against S. aureus and other common clinical 
pathogens. 
A condition observed in vivo that did not exist in vitro was exudate leaving the 
fresh implantation site. The exudate included blood and serous discharge in the first 
few days post-surgery, followed by necrotic tissue and pus as infection developed. 
This exudate soaked into the CSA-13 treated pad. The exudate hardened and formed 
a crust. This may have precluded the CSA-13 from diffusing into the wound site, 
when the intended delivery method, according to the previously stated in vitro testing, 
would deliver CSA-13 in the presence of moisture for proper treatment. Thus, 
effective delivery of the antimicrobial may have been compromised and efficacy not 
accurately represented. In addition, the motion of the soft tissues in the proximal 
ends of the fibularis tertius and extensor digitorum longus muscles at the implant site 
pressed and withdrew against the skin-pad interface. This may have also led to 
prevention of constant and complete contact between the delivery device and the 
skin-implant interface. 
These delivery device limitations, probably compounded by the rigorous in 
vivo model, suggest that CSA-13 should not be discounted as an effective bactericidal 
treatment until tested in a less rigorous in vivo model. Such experimentation could 
allow for a more complete understanding of CSA-13's infection prevention qualities 
in osseointegrated implants. 
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The data suggests that implant-skin attachment was essential before 
antimicrobials could be determined efficacious. Aggressive soft tissue motion and 
animal behavior may result in an over-challenging environment. This study 
reinforced the importance of limiting soft tissue motion around percutaneous devices 
in order to prevent infection and micromotion leading to implant loosening. This 
conclusion is in agreement with that made by Pendegrass et al. as determined in a 
34 33 
goat model as well as Branemark et al., as shown in human studies. Following 
this dermal attachment to the implant to limit soft tissue motion around 
osseointegrated implants, antimicrobials may be used as secondary barriers to prevent 
infection. 
Future Studies 
Possible future studies include testing for percutaneous implant dermal 
attachment in a less-rigorous animal model. Following this dermal attachment 
success, CSA-13 in alternative delivery forms as well as other antimicrobials maybe 
tested as secondary barriers to infection in osseointegrated implants. This will be 
used to determine possible antimicrobial effects on the skin seal around percutaneous 
implants as well as sound human skin. A one stage osseointegration procedure could 
be examined and multiple implant designs could be compared including microscopic 
porous coating, threaded, and macroscopic porous coating. 
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tested as secondary barriers to infection in osseointegrated implants. This will be 
used to determine possible antimicrobial effects on the skin seal around percutaneous 
implants as well as sound human skin. A one stage osseointegration procedure could 
be examined and multiple implant designs could be compared including microscopic 
porous coating, threaded, and macroscopic porous coating. 
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